The combined use of Pexidartinib and Sotuletinib (BLZ945), another CSF-1R inhibitor, reduced the proliferation of tumor cells, their spheroid formation ability, as well induced apoptosis in correlation with CSF-1R levels in TGCT [70]. The gene discussed is CSF1R; the disease is neoplasm.